Astatine-211 based radionuclide therapy: Current clinical trial landscape
- PMID: 36687417
- PMCID: PMC9859440
- DOI: 10.3389/fmed.2022.1076210
Astatine-211 based radionuclide therapy: Current clinical trial landscape
Abstract
Astatine-211 (211At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.
Keywords: alpha particle; astatine-211; clinical trial; human; radionuclide; targeted alpha therapy.
Copyright © 2023 Albertsson, Bäck, Bergmark, Hallqvist, Johansson, Aneheim, Lindegren, Timperanza, Smerud and Palm.
Conflict of interest statement
PA, TB, KS, SP, EA, and SL are co-founders of Aprit Biotech AB. EA and SL are the co-founders of Atley Solutions AB. KS is the founder of Smerud Medical Research Group. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications.Pharmaceutics. 2020 Dec 31;13(1):49. doi: 10.3390/pharmaceutics13010049. Pharmaceutics. 2020. PMID: 33396374 Free PMC article. Review.
-
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Expert Opin Biol Ther. 2016 Aug;16(8):1035-47. doi: 10.1080/14712598.2016.1185412. Epub 2016 May 19. Expert Opin Biol Ther. 2016. PMID: 27145158 Free PMC article. Review.
-
Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):192-217. doi: 10.1007/s00259-019-04475-5. Epub 2019 Aug 30. Eur J Nucl Med Mol Imaging. 2020. PMID: 31471713
-
Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.Sci Rep. 2015 Jul 14;5:12025. doi: 10.1038/srep12025. Sci Rep. 2015. PMID: 26169786 Free PMC article.
-
Targeted alpha therapy: part I.Curr Radiopharm. 2011 Jul;4(3):176. doi: 10.2174/1874471011104030176. Curr Radiopharm. 2011. PMID: 22201706
Cited by
-
Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications.Pharmaceuticals (Basel). 2023 Nov 17;16(11):1622. doi: 10.3390/ph16111622. Pharmaceuticals (Basel). 2023. PMID: 38004486 Free PMC article. Review.
-
Enhancing the Stability of 211At Radiopharmaceuticals: Insights from Ortho-Substituent Strategies.ACS Med Chem Lett. 2025 Mar 20;16(4):504-507. doi: 10.1021/acsmedchemlett.5c00102. eCollection 2025 Apr 10. ACS Med Chem Lett. 2025. PMID: 40236551 Free PMC article.
-
Copper-mediated radiochemistry: historical impact, current trends, and future possibilities.Npj Imaging. 2025 Jun 10;3:25. doi: 10.1038/s44303-025-00087-x. eCollection 2025. Npj Imaging. 2025. PMID: 40510251 Free PMC article. Review.
-
Alpha-Emitting Radionuclides: Current Status and Future Perspectives.Pharmaceuticals (Basel). 2024 Jan 8;17(1):76. doi: 10.3390/ph17010076. Pharmaceuticals (Basel). 2024. PMID: 38256909 Free PMC article. Review.
-
Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium.Front Nucl Med. 2024 Mar 28;4:1355912. doi: 10.3389/fnume.2024.1355912. eCollection 2024. Front Nucl Med. 2024. PMID: 39355215 Free PMC article. Review.
References
-
- Corson DR, MacKenzie KR, Segrè E. Possible production of radioactive isotopes of element 85. Phys Rev. (1940) 57:459. 10.1103/PhysRev.57.459 - DOI
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources